BMO: Eli Lilly and Co's Alzheimer's drug is expected to generate revenue of $7.1 billion, which is better than Biogen's competitor.

According to BMO reports, eli lilly and co's newly approved Alzheimer's drug donanemab could bring in peak sales of up to $7.1 billion for the company.

Zhitong Finance11:59

Lilly's New Alzheimer's Drug Could Generate $7.1B in Sales: Analyst

Seeking Alpha01:09

Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More

Yahoo Finance00:37

Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst

On Tuesday, the FDA approved Eli Lilly and Co's (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.Once-monthly, Kisunla is th

Benzinga00:13

Global Equities Roundup: Market Talk

The latest Market Talks covering Equities. Published exclusively on Dow Jones Newswires throughout the day. 1017 ET - Eli Lilly's new Alzheimer's drug Kisunla, which was approved by the FDA on Tuesda

WSJJul 3 22:17

Eli Lilly and Co has finally received approval from the USA's FDA, and there will be a two-horse race in the field of Alzheimer's disease.

Eli Lilly and Co executives wrote that Kisunla has shown a very meaningful effect, and patients urgently need this effective treatment plan.

cls.cnJul 3 08:46